My Recent Bone Imaging Scan Results.

[RalphieJr64]

Hello everyone. I've been on a clinical trial for the last nine months of Olaparib (Lynparza) and Cediranib. It has given me good results in being my PSA reading has gone down to 0.03, and when I started it was at 7.0 and my spots on my lymph nodes and liver has gone down considerably .You can read my bio for my past. I always had a lesion on my right pelvic area, but it hasn't bothered me for a while now. I started experiencing pain in my right pelvic and hip area a few weeks ago. Just got my results with my bone scan I had a few days ago. I now have new lesion growth on my right femur as well as mild lesions on my spine, skull and shoulders. I go in for consultation with a urologist-radiologist tomorrow. Has anyone experienced more bone mets even though your other organs involved are responding to treatment. I am also getting mild head and neck discomfort.

[Drcrunch]

Are you still on lymparza? What was you mutation, brca 1 or 2?

[RalphieJr64 in reply to Drcrunch]

BRCA 2, yes I'm still on the clinical trial that includes Lynparza.

[Hidden]

In your bio, you said you were going on Zytiga. Did they take you off Zytiga for the trial? Also curious if they did genetic testing before trial started?

[RalphieJr64 in reply to Hidden]

Zytiga wasn't working. Yes I had genetic testing before this trial.

[Hidden in reply to RalphieJr64]

Do you know if you had radiographic progression before going off Zytiga or was it just PSA progression?

[RalphieJr64 in reply to Hidden]

Hell Gregg, the PSA progression and the new mass on my liver got me off Zytiga and accepted into this clinical trial.

[Hidden in reply to RalphieJr64]

Sounds like you made a good choice.

[Drcrunch]

Unusual to have new Mets when you psa is so low or undetectable. Do they say you have some neuroendocrine features in your prostate cells. Check that out.

[RalphieJr64 in reply to Drcrunch]

Thank you. My Oncologist never mentioned about it being neuroendocrine. I hope it isn't because that could be a totally different cancer that doesn't end well.

[Tall_Allen]

PSA is just one of several biomarkers. Cediranib is a VEGF inhibitor which means it suppresses the formation of blood vessels into the tumors. It is the blood supply that leaks PSA into the serum from where it can be detected, but some tumors (hypoxic ones) can survive fine without a blood supply. PCa (vs other kinds of cancer) seems particularly prone to developing hypoxic tumors, and probably Cediranib selects for those. VEGF inhibitors used alone have not been found to be beneficial for prostate cancer, but your clinical trial will tell us whether the combination with a PARP inhibitor may be beneficial. So it sounds like the Cediranib is suppressing your PSA without suppressing the cancer, but hopefully the Lynparza is still slowing it down. You have to use imaging to tell you that.

[RalphieJr64 in reply to Tall_Allen]

Thank you Allen.